NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One shot to fight blindness? gene therapy trial aims to replace frequent eye injections
Disease control Recruiting nowThis study is testing whether a single gene therapy injection can control wet age-related macular degeneration (a leading cause of blindness) as well as or better than the current standard of care, which requires eye injections every 1-4 months. About 284 participants, both new a…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Tiny eye implant could replace frequent injections for blinding disease
Disease control Recruiting nowThis study is testing a new, slow-release implant placed in the eye to treat 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. It aims to see if this implant is safe and can work longer than the current standard treatment of regular eye injections. The…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1, PHASE2 • Sponsor: Alcon Research • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
One shot could replace years of eye injections for leading cause of blindness
Disease control Recruiting nowThis study is testing a single gene therapy injection for wet age-related macular degeneration (AMD), a major cause of vision loss. It aims to see if this one-time treatment can work as well as or better than the current standard of frequent eye injections. The trial will enroll …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis large, late-stage trial is testing whether a single gene therapy injection into the eye (called LX102) can work as well as or better than the standard monthly eye injections for wet age-related macular degeneration. The main goal is to see if the one-time treatment can impro…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
One-Shot vision treatment could replace yearly eye injections
Disease control Recruiting nowThis trial is testing a new, one-time eye injection called 4D-150 for adults with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal is to see if this single treatment can control the disease and maintain vision for up to two years, potentia…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC